Entrada Therapeutics, Inc.

From time to time, claims are made against the Company in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties, and unfavorable outcomes could occur. In the opinion of management, the resolution of these matters, if any, will not have a material adverse impact on the Company’s financial position or results of operations.

On February 7, 2025, Ohio State Innovation Foundation (“OSIF”) filed a complaint in the United States District Court for the Southern District of Ohio against us, alleging claims for breach of contract related to the License Agreement, by and between us and OSIF, dated as of December 14, 2018, as amended. The dispute concerned our payment of sublicensing fees to OSIF arising from the sublicense agreement with Vertex, which was amended in October 2023. The complaint sought compensatory damages, pre-judgment and post-judgment interest, and attorneys' fees and costs, as well as an order for specific performance. We disputed OSIF’s claims. On August 22, 2025, we filed a Partial Motion to Dismiss under Federal Rule of Civil Procedure 12(b)(6) in the United States District Court for the Southern District of Ohio ("Partial Motion to Dismiss") along with a memorandum in support of the Partial Motion to Dismiss. On September 18, 2025, OSIF filed a Notice of Voluntary Dismissal Without Prejudice in the United States District Court for the Southern District of Ohio (the "Notice of Dismissal"). In the Notice of Dismissal, OSIF dismissed all of its claims against us.